» Articles » PMID: 34579743

Chemotherapy-triggered Changes in Stromal Compartment Drive Tumor Invasiveness and Progression of Breast Cancer

Abstract

Background: Chemotherapy remains a standard treatment option for breast cancer despite its toxic effects to normal tissues. However, the long-lasting effects of chemotherapy on non-malignant cells may influence tumor cell behavior and response to treatment. Here, we have analyzed the effects of doxorubicin (DOX) and paclitaxel (PAC), commonly used chemotherapeutic agents, on the survival and cellular functions of mesenchymal stromal cells (MSC), which comprise an important part of breast tumor microenvironment.

Methods: Chemotherapy-exposed MSC (DOX-MSC, PAC-MSC) were co-cultured with three breast cancer cell (BCC) lines differing in molecular characteristics to study chemotherapy-triggered changes in stromal compartment of the breast tissue and its relevance to tumor progression in vitro and in vivo. Conditioned media from co-cultured cells were used to determine the cytokine content. Mixture of BCC and exposed or unexposed MSC were subcutaneously injected into the immunodeficient SCID/Beige mice to analyze invasion into the surrounding tissue and possible metastases. The same mixtures of cells were applied on the chorioallantoic membrane to study angiogenic potential.

Results: Therapy-educated MSC differed in cytokine production compared to un-exposed MSC and influenced proliferation and secretory phenotype of tumor cells in co-culture. Histochemical tumor xenograft analysis revealed increased invasive potential of tumor cells co-injected with DOX-MSC or PAC-MSC and also the presence of nerve fiber infiltration in tumors. Chemotherapy-exposed MSC have also influenced angiogenic potential in the model of chorioallantoic membrane.

Conclusions: Data presented in this study suggest that neoadjuvant chemotherapy could possibly alter otherwise healthy stroma in breast tissue into a hostile tumor-promoting and metastasis favoring niche. Understanding of the tumor microenvironment and its complex net of signals brings us closer to the ability to recognize the mechanisms that prevent failure of standard therapy and accomplish the curative purpose.

Citing Articles

Cancer treatments as paradoxical catalysts of tumor awakening in the lung.

Nicolas E, Kosmider B, Cukierman E, Borghaei H, Golemis E, Borriello L Cancer Metastasis Rev. 2024; 43(4):1165-1183.

PMID: 38963567 PMC: 11554904. DOI: 10.1007/s10555-024-10196-5.


The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer.

Dou T, Li J, Zhang Y, Pei W, Zhang B, Wang B Front Immunol. 2024; 15:1368687.

PMID: 38487526 PMC: 10937353. DOI: 10.3389/fimmu.2024.1368687.


The role of host response to chemotherapy: resistance, metastasis and clinical implications.

Deo A, Sleeman J, Shaked Y Clin Exp Metastasis. 2023; 41(4):495-507.

PMID: 37999904 DOI: 10.1007/s10585-023-10243-5.


Chemoresistant fibroblasts dictate neoadjuvant chemotherapeutic response of head and neck cancer via TGFα-EGFR paracrine signaling.

Su L, Wu S, Huang C, Zhuo X, Chen J, Jiang X NPJ Precis Oncol. 2023; 7(1):102.

PMID: 37821657 PMC: 10567732. DOI: 10.1038/s41698-023-00460-2.


The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer.

Zohair B, Chraa D, Rezouki I, Benthami H, Razzouki I, Elkarroumi M Front Immunol. 2023; 14:1201632.

PMID: 37753093 PMC: 10518422. DOI: 10.3389/fimmu.2023.1201632.


References
1.
Zahalka A, Frenette P . Nerves in cancer. Nat Rev Cancer. 2020; 20(3):143-157. PMC: 7709871. DOI: 10.1038/s41568-019-0237-2. View

2.
Karagiannis G, Pastoriza J, Wang Y, Harney A, Entenberg D, Pignatelli J . Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci Transl Med. 2017; 9(397). PMC: 5592784. DOI: 10.1126/scitranslmed.aan0026. View

3.
Conceicao F, Sousa D, Paredes J, Lamghari M . Sympathetic activity in breast cancer and metastasis: partners in crime. Bone Res. 2021; 9(1):9. PMC: 7864971. DOI: 10.1038/s41413-021-00137-1. View

4.
Mehraj U, Dar A, Wani N, Mir M . Tumor microenvironment promotes breast cancer chemoresistance. Cancer Chemother Pharmacol. 2021; 87(2):147-158. DOI: 10.1007/s00280-020-04222-w. View

5.
Babajani A, Soltani P, Jamshidi E, Farjoo M, Niknejad H . Recent Advances on Drug-Loaded Mesenchymal Stem Cells With Anti-neoplastic Agents for Targeted Treatment of Cancer. Front Bioeng Biotechnol. 2020; 8:748. PMC: 7390947. DOI: 10.3389/fbioe.2020.00748. View